Strategy to achieve biomarker-driven immunosuppression after solid organ transplantation by an academic-industry partnership within the European BIO-DrIM consortium
Journal Title: Advances in Precision Medicine - Year 2016, Vol 1, Issue 1
Abstract
Solid organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure as it improves both quality of life and survival. Despite the progress in short-term graft survival, that is closely associated with the impressive reduction of acute rejections within the first year, long-term graft and patient survival remain almost unchanged and unsatisfactory. Incomplete control of chronic allograft injury but particularly the adverse effects of long-term immunosuppression, such as graft toxicity, diabetes, cardiovascular events, infections, and tumours continue to challenge the long-term success. In general, immunosuppression is applied as one-size-fits-all strategy. This can result in over- and under-immunosuppression of patients with low and high allo-responsiveness, respectively. Trial- and -error strategies to minimize or even completely wean of immunosuppression have a high failure rate. Consequently, there is an unmet medical need to develop biomarkers allowing objective risk stratification of transplant patients. To achieve this goal, we engaged in an academic-industrial partnership. The central focus of the European-wide BIO-DrIM consortium (BIOmarker-Driven IMmmunosuppression) is the implementation of biomarker-guided strategies for personalizing immunosuppress- ion to improve the long-term outcome and to decrease the adverse effects and costs of chronic immunosuppression in solid organ transplant patients. The concept includes four innovative investigator-driven clinical trials designed by the consortium.
Authors and Affiliations
Hans-Dieter Volk, Bernhard Banas, Frederike Bemelman, Oriol Bestard4, Sophie Brouard5,Cristina Cuturi, Josep M Grinyó, Maria Hernandez-Fuentes, Martina Koch, Björn Nashan,Irene Rebollo-Mesa, Alberto Sanchez-Fueyo, Birgit Sawitzki, Ineke J M ten Berge, Ondrej Viklicky, Kathryn Wood K9 and Petra Reinke
Keywords
Related Articles
- EP ID EP679276
- DOI -
- Views 202
- Downloads 0
Success factors in drug discovery and development
The article aimed to give a personal perspective on drug discovery and development. The author has worked both in Big Pharma as a scientist and manager and more recently also in start-up biotech companies. Drug companies...
What makes a good biomarker?
The last decade has seen an extraordinary amount of effort devoted in biomedical research to the field of biomarkers. There have been some notable successes with novel markers being adopted into clinical practice bringin...
Validation of novel multiplex technologies
Cytokine and chemokine levels in body fluid provide information of altered conditions in patients. The parallel analysis of multiple factors, such as cytokines, from small sample sizes is an interesting approach for the...
Precision medicine: do not neglect the hurdles
Tremendous expectations have been connected with precision medicine in the past years. Beside the advantages that this type of therapy offers we should be aware of its challenges too. In this issue we will highlight on...
Strategy to achieve biomarker-driven immunosuppression after solid organ transplantation by an academic-industry partnership within the European BIO-DrIM consortium
Solid organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure as it improves both quality of life and survival. Despite the progress in short-term graft survival, that is closely asso...